Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients

Karen Yao, Susan Gagnon, Nahid Akhyani, Elizabeth Williams, Julie Fotheringham, Elliot Frohman, Olaf Stuve, Nancy L Monson, Michael K. Racke, Steven Jacobson

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The α4 integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopahty (PML) in two multiple sclerosis (MS) and one Crohn's disease patients. Impaired immune surveillance due to natalizumab treatment may have contributed to the JCV reactivation. As HHV-6 has been suggested to play a role in MS, we asked whether this virus could also have been reactivated during natalizumab therapy. Matched sera and CSF from a limited set of MS patients treated with and without natalizumab were examined for evidence of HHV-6. In Addition, we also superinfected a persistent JC virus infected glial cell with HHV-6A to determine if JC virus can be increased. Elevated serum HHV6 IgG and HHV-6A DNA was detected in the CSF of a subser of patients but not controls. We confirmed that superinfection with HHV-6 of a JC virus infected glial cells increased expression of JCV. These results support the hypothesis that treatment with natalizumab may be associated with reduced immune surveillance resulting in reactivation of viruses associated with MS pathogenesis.

Original languageEnglish (US)
Article numbere2028
JournalPLoS One
Volume3
Issue number4
DOIs
StatePublished - Apr 30 2008

Fingerprint

Human herpesvirus 6
JC polyomavirus
Human Herpesvirus 6
sclerosis
Viruses
JC Virus
Multiple Sclerosis
neuroglia
Neuroglia
viruses
Superinfection
Crohn disease
Integrins
monitoring
Immune System Diseases
integrins
Serum
Crohn Disease
Immunoglobulin G
Natalizumab

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Yao, K., Gagnon, S., Akhyani, N., Williams, E., Fotheringham, J., Frohman, E., ... Jacobson, S. (2008). Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One, 3(4), [e2028]. https://doi.org/10.1371/journal.pone.0002028

Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. / Yao, Karen; Gagnon, Susan; Akhyani, Nahid; Williams, Elizabeth; Fotheringham, Julie; Frohman, Elliot; Stuve, Olaf; Monson, Nancy L; Racke, Michael K.; Jacobson, Steven.

In: PLoS One, Vol. 3, No. 4, e2028, 30.04.2008.

Research output: Contribution to journalArticle

Yao, K, Gagnon, S, Akhyani, N, Williams, E, Fotheringham, J, Frohman, E, Stuve, O, Monson, NL, Racke, MK & Jacobson, S 2008, 'Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients', PLoS One, vol. 3, no. 4, e2028. https://doi.org/10.1371/journal.pone.0002028
Yao, Karen ; Gagnon, Susan ; Akhyani, Nahid ; Williams, Elizabeth ; Fotheringham, Julie ; Frohman, Elliot ; Stuve, Olaf ; Monson, Nancy L ; Racke, Michael K. ; Jacobson, Steven. / Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. In: PLoS One. 2008 ; Vol. 3, No. 4.
@article{606e263de7e846bc8b15d93315343dcc,
title = "Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients",
abstract = "The α4 integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopahty (PML) in two multiple sclerosis (MS) and one Crohn's disease patients. Impaired immune surveillance due to natalizumab treatment may have contributed to the JCV reactivation. As HHV-6 has been suggested to play a role in MS, we asked whether this virus could also have been reactivated during natalizumab therapy. Matched sera and CSF from a limited set of MS patients treated with and without natalizumab were examined for evidence of HHV-6. In Addition, we also superinfected a persistent JC virus infected glial cell with HHV-6A to determine if JC virus can be increased. Elevated serum HHV6 IgG and HHV-6A DNA was detected in the CSF of a subser of patients but not controls. We confirmed that superinfection with HHV-6 of a JC virus infected glial cells increased expression of JCV. These results support the hypothesis that treatment with natalizumab may be associated with reduced immune surveillance resulting in reactivation of viruses associated with MS pathogenesis.",
author = "Karen Yao and Susan Gagnon and Nahid Akhyani and Elizabeth Williams and Julie Fotheringham and Elliot Frohman and Olaf Stuve and Monson, {Nancy L} and Racke, {Michael K.} and Steven Jacobson",
year = "2008",
month = "4",
day = "30",
doi = "10.1371/journal.pone.0002028",
language = "English (US)",
volume = "3",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients

AU - Yao, Karen

AU - Gagnon, Susan

AU - Akhyani, Nahid

AU - Williams, Elizabeth

AU - Fotheringham, Julie

AU - Frohman, Elliot

AU - Stuve, Olaf

AU - Monson, Nancy L

AU - Racke, Michael K.

AU - Jacobson, Steven

PY - 2008/4/30

Y1 - 2008/4/30

N2 - The α4 integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopahty (PML) in two multiple sclerosis (MS) and one Crohn's disease patients. Impaired immune surveillance due to natalizumab treatment may have contributed to the JCV reactivation. As HHV-6 has been suggested to play a role in MS, we asked whether this virus could also have been reactivated during natalizumab therapy. Matched sera and CSF from a limited set of MS patients treated with and without natalizumab were examined for evidence of HHV-6. In Addition, we also superinfected a persistent JC virus infected glial cell with HHV-6A to determine if JC virus can be increased. Elevated serum HHV6 IgG and HHV-6A DNA was detected in the CSF of a subser of patients but not controls. We confirmed that superinfection with HHV-6 of a JC virus infected glial cells increased expression of JCV. These results support the hypothesis that treatment with natalizumab may be associated with reduced immune surveillance resulting in reactivation of viruses associated with MS pathogenesis.

AB - The α4 integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopahty (PML) in two multiple sclerosis (MS) and one Crohn's disease patients. Impaired immune surveillance due to natalizumab treatment may have contributed to the JCV reactivation. As HHV-6 has been suggested to play a role in MS, we asked whether this virus could also have been reactivated during natalizumab therapy. Matched sera and CSF from a limited set of MS patients treated with and without natalizumab were examined for evidence of HHV-6. In Addition, we also superinfected a persistent JC virus infected glial cell with HHV-6A to determine if JC virus can be increased. Elevated serum HHV6 IgG and HHV-6A DNA was detected in the CSF of a subser of patients but not controls. We confirmed that superinfection with HHV-6 of a JC virus infected glial cells increased expression of JCV. These results support the hypothesis that treatment with natalizumab may be associated with reduced immune surveillance resulting in reactivation of viruses associated with MS pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=44349110622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349110622&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0002028

DO - 10.1371/journal.pone.0002028

M3 - Article

C2 - 18446218

AN - SCOPUS:44349110622

VL - 3

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e2028

ER -